# Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

> **NCT06045247** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Large B-cell Lymphoma

## Interventions

- **DRUG:** Prednisone
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Epcoritamab

## Key facts

- **NCT ID:** NCT06045247
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-05
- **Primary completion:** 2028-07-31
- **Final completion:** 2030-07-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06045247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06045247, "Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06045247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*